LUCD - Lucid Diagnostics Inc.
After hours:
| Previous Close | 1.5000 |
| Open | 1.5000 |
| Bid | 1.5000 x 1000 |
| Ask | 1.5100 x 800 |
| Day's Range | 1.4200 - 1.5300 |
| 52 Week Range | 1.1050 - 3.6400 |
| Volume | |
| Avg. Volume | 79,459 |
| Market Cap | 62.78M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6000 |
| Earnings Date | Mar 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.76 |
Simply Wall St.Lucid Diagnostics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
Lucid Diagnostics ( NASDAQ:LUCD ) First Quarter 2023 Results Key Financial Results Net loss: US$16.2m (loss widened by...
- Simply Wall St.
Are Investors Undervaluing Lucid Diagnostics Inc. (NASDAQ:LUCD) By 43%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Lucid Diagnostics fair value estimate is US$2.58 Lucid...
- Thomson Reuters StreetEvents
Q4 2022 Lucid Diagnostics Inc Earnings Call
Q4 2022 Lucid Diagnostics Inc Earnings Call
Business WirePAVmed and Lucid Diagnostics Provide Strategic Business Update
NEW YORK, January 17, 2023--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or "Lucid Diagnostics"), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc. ("Veris"), a private digital health company focused on enhanced personalized cancer care, today provided a
Business WirePAVmed and Lucid Diagnostics to Provide Strategic Business Update
NEW YORK, January 11, 2023--Companies will present refinements to their business strategy as each continue to the benefit patients in need and create value for shareholders.
Business WirePAVmed Partners with Novosound on Ultrasound Imaging Technology
NEW YORK, December 22, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has entered into a license option and joint research and development agreement with Novosound Ltd. ("Novosound"), a venture-backed technology company based in Glasgow, Scotland, to explore applying Novosound’s proprietary flexible thin-film ultrasound technology in me
Business WirePAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
NEW YORK, December 15, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), has commercially launched its Veris Cancer Care Platform™ ("Veris CCP"). Veris executed its first commercial contract with New Jersey Cancer Care, PA ("NJCC"), a leading oncology practice and membe
- Simply Wall St.
Here's Why Lucid Diagnostics (NASDAQ:LUCD) Must Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Business WireLucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
NEW YORK, December 08, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that the Company was selected as one of ten finalists for the Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry ("MD+DI"), a leading publication serving manufacturers of medical devices and in vitro diagnostics products,
Business WireLucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
NEW YORK, December 01, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Suman M. Verma, M.D., Ph.D., Lucid’s Chief Scientific Officer, presented real-world data on its EsoCheck® Cell Collection Device ("EsoCheck") at the American Association for Cancer Research’s ("AACR") Special Conference: Precision Prevention, Early Detect
Business WirePAVmed Provides Business Update and Third Quarter 2022 Financial Results
NEW YORK, November 15, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the three and nine months ended September 30, 2022.
Business WireLucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
NEW YORK, November 14, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and presented financial results for the three and nine months ended September 30, 2022.
Business WireLucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
NEW YORK, November 10, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid", the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Lishan Aklog, M.D., the Lucid’s Chairman and Chief Executive Officer, will present an overview of the Company at the CG MedTech, Diagnostics and Digital Health & Services Forum taking place on November 17, 2022 from 11:00 am to 11:25 am EST
Business WireLucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
NEW YORK, November 09, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid", the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced the commencement of production of its EsoCheck® Esophageal Cell Collection Devices ("EsoCheck") at Coastline International, Inc. ("Coastline"), a high-volume manufacturer headquartered in San Diego, CA with plants in Mexico. The Company has work
Business WireLucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
NEW YORK, November 02, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the Company will host a business update conference call and webcast on Monday, November 14, 2022, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman, and Chief Executive Officer, will provide a business update including an overview of the Company’s operation
Business WireLucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
NEW YORK, August 15, 2022--Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
- Simply Wall St.
What Type Of Shareholders Make Up Lucid Diagnostics Inc.'s (NASDAQ:LUCD) Share Registry?
A look at the shareholders of Lucid Diagnostics Inc. ( NASDAQ:LUCD ) can tell us which group is most powerful...
Business WireLucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
NEW YORK, August 11, 2022--Lucid Diagnostics Inc. announced its subsidiary, LucidDx Labs Inc., launched four new Lucid Test Centers in California, Texas Florida and Ohio.
Business WireNewly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
NEW YORK, August 04, 2022--Newly published AGA update supports esophageal precancer screening to prevent esophageal cancer using EsoGuard on samples collected with its EsoCheck.
Business WireLucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements
NEW YORK, August 02, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid", the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that its wholly-owned CLIA-certified and CAP-accredited laboratory, LucidDx Labs Inc. ("LucidDx Labs"), has entered into participating provider agreements with preferred provider organizations Prime Healthcare, Three Rivers Provider Network, and Ga
Business WireLucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022
NEW YORK, August 01, 2022--Lucid Diagnostics Inc. announced that the Company will host a business update conference call on Monday, August 15, 2022, at 4:30 PM EDT.
Business WireLucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
NEW YORK, July 18, 2022--Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
- Simply Wall St.
Is Lucid Diagnostics (NASDAQ:LUCD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...